SCHEMBL4476375

SCHEMBL4476375

CCCCc1ccc(C([NH])=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.62
PLK1 P53350 1/20 0.62
THRA P10827 7/20 0.61
THRB P10828 7/20 0.61
ALDH1A1 P00352 3/20 0.58
HPGD P15428 1/20 0.58
HSD17B10 Q99714 1/20 0.58
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RARA P10276 1/20 0.54
MAPT P10636 1/20 0.54
MTOR P42345 1/20 0.54
TRPV1 Q8NER1 1/20 0.54
PLA2G1B P04054 1/20 0.51
ATG4B Q9Y4P1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9126722 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL75643 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL10666525 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL5187964 0.88 PLK1 (0.60) RARBPLK1THRATHRBALDH1A1
SCHEMBL1404028 0.83 RARB (0.67) RARBPLK1THRATHRBALDH1A1
SCHEMBL2564366 0.83 RARB (0.67) RARBPLK1THRATHRBALDH1A1
SCHEMBL13950912 0.83 RARB (0.67) RARBPLK1THRATHRBALDH1A1
SCHEMBL9693784 0.82 RARB (0.65) RARBPLK1THRATHRBALDH1A1
SCHEMBL967078 0.82 HSD17B10 (0.67) RARBPLK1THRATHRBALDH1A1
SCHEMBL181230 0.82 RARB (0.89) RARBPLK1THRATHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569646-B1 Group IVB transition metal compounds EXXONMOBIL CHEMICAL PATENTS INC. (US) 2009-08-04 US claimed
US-6617466-B1 Having a heteroatom ligand containing an element with a coordination number of three from Group V A or a coordination number of two from Group VI A attached to the ring through a hydrocarbylene, silane or germanium group EXXONMOBIL CHEMICAL PATENTS INC. 2003-09-09 US claimed
US-7569646-B1 Group IVB transition metal compounds EXXONMOBIL CHEMICAL PATENTS INC. (US) 2009-08-04 US disclosed
US-RE40234-E1 Process for producing crystalline poly-α-olefins with a monocyclopentadienyl transition metal catalyst system EXXONMOBIL CHEMICAL PATENTS, INC. 2008-04-08 US disclosed
US-7342039-B2 Substituted indole oximes WYETH (US) 2008-03-11 US disclosed
EP-1110974-B1 Method for preparing a supported activator component EXXONMOBIL CHEM PATENTS INC (US) 2007-11-28 EP disclosed
US-7205364-B1 Olefin polymerization catalysts EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-04-17 US disclosed
US-20060178491-A1 Olefin polymerization catalysts CANICH JO ANN M 2006-08-10 US disclosed
EP-1667670-A1 4-(1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-14 EP disclosed
US-7041841-B1 Process for producing crystalline poly-α-olefins with a monocyclopentadienyl transition metal catalyst system EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-05-09 US disclosed
US-20050119326-A1 Substituted aryloximes WYETH (US) 2005-06-02 US disclosed
US-6617466-B1 Having a heteroatom ligand containing an element with a coordination number of three from Group V A or a coordination number of two from Group VI A attached to the ring through a hydrocarbylene, silane or germanium group EXXONMOBIL CHEMICAL PATENTS INC. 2003-09-09 US disclosed
EP-0548277-B1 PROCESS FOR PRODUCING CRYSTALLINE POLY-ALPHA-OLEFINS WITH A MONOCYCLOPENTADIENYL TRANSITION METAL CATALYST SYSTEM EXXONMOBIL CHEM PATENTS INC (US) 2001-11-28 EP disclosed
EP-0765879-B1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO CO (JP) 2001-02-14 EP disclosed
US-5861429-A MITICIDES AND ANTHELMINTICS SANKYO COMPANY, LIMITED (JP) 1999-01-19 US disclosed
EP-0765879-A1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO COMPANY LIMITED (JP) 1997-04-02 EP disclosed
EP-0275077-B1 ANTHRAQUINONE COMPOUNDS AND POLARIZING FILM CONTAINING THE SAME MITSUBISHI KASEI CORPORATION (JP) 1992-02-05 EP disclosed
US-4921959-A POLARIZING FILMS, DICHROMISM MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1990-05-01 US disclosed
US-4841057-A POLARIZING FILMS; HIGH DICHROISM, PERFORMANCE MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1989-06-20 US disclosed
EP-0275077-A1 Anthraquinone compounds and polarizing film containing the same MITSUBISHI KASEI CORPORATION (JP) 1988-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119326-A1 Substituted aryloximes IDO2, TDO2, IDO1 RARB 2989/4885PLK1 2371/4885THRA 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.